Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

AbbVie Expects Solid FY22 As Botox, Skyrizi Power Q4 Earnings

AbbVie Inc (NYSE:ABBV) reports Q4 adjusted EPS of $3.31, higher than $2.92 reported a year ago and beating the consensus of $3.28.

  • Overall sales increased 7.4% Y/Y (7.5% on an operational basis) to $14.89 billion, missing the consensus of $14.98 billion.
  • The immunology portfolio generated $6.75 billion in sales, +13.2% (+13.3% on an operational basis). Humira sales increased 3.5% at $5.334 billion. Skyrizi sales reached $895 million, and Rinvoq jumped 84.4% to $517 million.
  • Hematologic oncology portfolio sales were $1.87 billion, +4.6% (+4.7% on an operational basis). Imbruvica sales decreased 2.7% to $1.38 billion. Venclexta revenues were up 33% to $488 million.
  • Sales from the neuroscience portfolio reached $1.65 billion, +19%. Aesthetics portfolio sales increased 23.3% (+22.8% on an operational basis) to $1.41 billion, with $626 million in Botox sales for cosmetic uses.
  • Adjusted gross margin expanded from 81.8% to 83.6%. The adjusted operating margin also improved from 46.9% to 49.3%.
  • FY22 guidance: AbbVie expects FY22 adjusted EPS of $14.00 - $14.20, versus the consensus of $13.99.
  • Price Action: ABBV shares are up 0.49% at $137.67 on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.